4.7 Article

Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET

期刊

CLINICAL CANCER RESEARCH
卷 27, 期 4, 页码 1058-1068

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-2770

关键词

-

类别

资金

  1. Stanford shared FACS facility
  2. Ben & Catherine Ivy Foundation
  3. Canary Foundation
  4. NCI [R01 1 CA201719-02, R01 CA23158201, P01 CA49605, P5P30CA124435]
  5. Parker Institute for Cancer Immunotherapy
  6. Geneva University Hospitals
  7. Swiss Cancer League [BIL KLS 3806-02-2016]
  8. Fondation de Bienfaisance Valeria Rossi di Montelera
  9. American Society for Blood and Marrow Transplantation
  10. Dubois-Ferriere-Dinu-Lipatti Foundation
  11. Virginia and D.K. Ludwig Fund for Cancer Research
  12. Baldrick's/Stand Up 2 Cancer Pediatric Dream Team Trans-lational Cancer Research Grant

向作者/读者索取更多资源

The monitoring of CAR T-cell therapy primarily relies on quantification in peripheral blood, which may not reflect their distribution and activation status in tissues. This study evaluated the potential of antibody-based PET imaging for noninvasively visualizing CAR T cells.
Purpose: Immunomonitoring of chimeric antigen receptor (CAR) T cells relies primarily on their quantification in the peripheral blood, which inadequately quantifies their biodistribution and activation status in the tissues. Noninvasive molecular imaging of CART cells by PET is a promising approach with the ability to provide spatial, temporal, and functional information. Reported strategies rely on the incorporation of reporter transgenes or ex vivo biolabeling, significantly limiting the application of CAR T-cell molecular imaging. In this study, we assessed the ability of antibody-based PET (immunoPET) to noninvasively visualize CAR T cells. Experimental Design: After analyzing human CAR T cells in vitro and ex vivo from patient samples to identify candidate targets for immunoPET, we employed a syngeneic, orthotopic murine tumor model of lymphoma to assess the feasibility of in vivo tracking of CAR T cells by immunoPET using the Zr-89-DFO-anti-ICOS tracer, which we have previously reported. Results: Analysis of human CD19-CAR 'I' cells during activation identified the Inducible T-cell COStimulator (ICOS) as a potential target for immunoPET. In a preclinical tumor model, Zr-89-DFO-ICOS mAb PET-CT imaging detected significantly higher signal in specific bone marrow-containing skeletal sites of CAR T-cell-treated mice compared with controls. Importantly, administration of ICOS-targeting antibodies at tracer doses did not interfere with CAR T-cell persistence and function. Conclusions: This study highlights the potential of ICOS-immunoPET imaging for monitoring of CAR T-cell therapy, a strategy readily applicable to both commercially available and investigational CAR T cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据